IL11 and prostate cancer: Additionally, the data revealed that recombinant human IL-11 (Rh IL-11) exerted a cytoprotective effect against a range of DTX concentrations, indicating a potential mechanism by which IL-11 confers a survival benefit to prostate cancer cells (Fig. 4E, F).